Verve’s gene-editing therapy trial to lower cholesterol levels opens doors for use in CVDs:… EP News Bureau Nov 16, 2023 PCSK9 inhibitors, like VERVE-101, currently holds 20 per cent market share in the acute coronary syndrome market. PCSK9 inhibitors…
